Drug
BTZ-043 clinical trials
Also written BTZ-043.
- studies test it
- 5
- open now
- 2
- in phase 3
- 0
- first study started
- 2018
Keep track of what changes. Save the BTZ-043 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Studies by the year they started
5 studies that test it; most in 2023 (2)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2019 | 1 |
| 2023 | 2 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 0 · Other 5
Michael Hoelscher (4) · University College, London (1)
Often tested with
Tested in the same studies.
Ganfeborole (2) · Pretomanid (2) · Moxifloxacin (2) · Pyrazinamide (2) · Delpazolid (2) · Bedaquiline (1) · OPC-67683 (1) · Linezolid (1)
Studies
Open first, then newest update. How each study uses BTZ-043 is read from its arms, and is right about nine times in ten.
Testing it · 5
- Platform Assessing Regimens and Durations In a Global Multisite Consortium for TBRecruitingPhase 2University College, LondonNCT06114628Written as BTZ-043
- PanACEA - STEP2C -01RecruitingPhase 2Michael HoelscherNCT05807399Written as BTZ-043
- BTZ-043 Dose Evaluation in Combination and SelectionCompletedPhase 2Michael HoelscherNCT05926466Written as BTZ-043
- BTZ-043 - Multiple Ascending Dose (MAD) to Evaluate Safety, Tolerability and Early Bactericidal Activity (EBA)CompletedPhase 1/2Michael HoelscherNCT04044001Written as BTZ-043
- A Single Ascending Dose Study of BTZ043CompletedPhase 1Michael HoelscherNCT03590600Written as BTZ-043
Given in every arm · 2 — BTZ-043 is usual care beside what is tested
- Study of Combinations of Novel Promising Drugs for Pulmonary TuberculosisNot yet recruitingPhase 2TASK Applied ScienceNCT07773610Written as BTZ-043 250 mg or 500 mg
- Early Bactericidal Activity, Safety & Tolerability of Oral GSK3036656 in a Dual Combination With Novel and Established Antitubercular Agents, or Standard of Care in Adults With Rifampicin Susceptible Pulmonary TuberculosisCompletedPhase 2GlaxoSmithKlineNCT05382312Written as BTZ-043
Codes
What other systems call BTZ-043 · ClinicalTrials.gg INT016629
- Wikidata Q27278777btz-043One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| Wikidata | Q27278777 | btz-043 | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.